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ABSTRACT 
Activating mutations in KRAS are the hallmark genetic alterations in pancreatic 
ductal adenocarcinoma (PDAC) and the key drivers of its initiation and progression. 
Longstanding efforts to develop novel KRAS inhibitors have been based on the assumption 
that PDAC cells are addicted to activated KRAS, but this assumption remains 
controversial. In this study, we analyzed the requirement of endogenous Kras to maintain 
survival of murine PDAC cells, using an inducible shRNA-based system that enables 
temporal control of Kras expression. We found that the majority of murine PDAC cells 
analyzed tolerated acute and sustained Kras silencing by adapting to a reversible cell state 
characterized by differences in cell morphology, proliferative kinetics, and tumor-initiating 
capacity. While we observed no significant mutational or transcriptional changes in the 
Kras-inhibited state, global phosphoproteomic profiling revealed significant alterations in 
cell signaling, including increased phosphorylation of focal adhesion pathway components. 
Accordingly, Kras-inhibited cells displayed prominent focal adhesion plaque structures, 
enhanced adherence properties, and increased dependency on adhesion for viability in vitro. 
Overall, our results call into question the degree to which PDAC cells are addicted to 
activated KRAS, by illustrating adaptive non-genetic and non-transcriptional mechanisms 
of resistance to Kras blockade. However, by identifying these mechanisms, our work also 
provides mechanistic directions to develop combination strategies that can help enforce the 
efficacy of KRAS inhibitors.  
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INTRODUCTION 
Pancreatic cancer, of which 85% is pancreatic ductal adenocarcinoma (PDAC), is an 
aggressive disease that is largely refractory to frontline therapy (1). Although recent advances in 
multi-agent chemotherapy have increased median survival in advanced disease, the 5-year 
survival rate for PDAC patients remains low at 8% (2–4), making PDAC the third leading cause 
of cancer death in the United States (2) and underscoring an urgent need for novel therapies with 
improved efficacy and reduced toxicity. 
Genomic studies revealed that KRAS mutations are the hallmark genetic feature of PDAC 
(5–7).  KRAS encodes a GTPase that regulates diverse cellular processes, including proliferation 
and survival.  In cancer cells, somatic missense mutations render KRAS insensitive to GTPase-
activating proteins, resulting in the accumulation of GTP-bound KRAS and hyperactive effector 
signaling (8).  As oncogenic KRAS signaling potentially contributes to multiple facets of 
malignant transformation, its precise biological functions in cancer appear context-dependent 
and remain to be fully elucidated (9–12). 
The high frequency of activating KRAS mutations implies that oncogenic KRAS may 
drive PDAC initiation and progression.  Mouse models have demonstrated that mutant Kras 
expression in the mouse pancreas leads to the development of precursor pancreatic intraepithelial 
neoplasia (PanINs) and PDAC, confirming the role of oncogenic Kras in tumor initiation 
(9,13,14).  In contrast, the requirement of KRAS for PDAC maintenance remains unresolved.  
RNA interference-mediated knockdown of endogenous KRAS in human cell lines demonstrated 
variable dependency of PDAC cells on KRAS for survival (15).  Accordingly, gene expression 
profiling of human PDAC tumors revealed distinct molecular subtypes associated with varying 
KRAS dependencies (16).  In established Kras-driven mouse PDAC tumors, the withdrawal of 
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oncogenic Kras transgene expression resulted in rapid tumor regression, suggesting that 
sustained oncogenic Kras expression is essential for maintenance (9,11).  Although the removal 
of oncogenic Kras is initially detrimental, tumor relapse via doxycycline-independent expression 
of the oncogenic Kras transgene and Kras-independent bypass mechanisms was observed 
(17,18). 
Since at least a subset of PDAC cells and tumors exhibit KRAS oncogene addiction, 
KRAS inhibition is a compelling therapeutic approach.  Unfortunately, effective 
pharmacological KRAS inhibitors have not yet been developed (8).  A deeper understanding of 
the essentiality of KRAS for tumor maintenance and the degree of KRAS inhibition required to 
impair PDAC cell survival could provide insights into the role of KRAS in PDAC and facilitate 
the development of KRAS-directed therapies.  Given that resistance against single-agent targeted 
therapies frequently emerges after prolonged treatment (19,20), it is critical to preemptively 
strategize treatment methods to circumvent resistance.  Studies of cancer therapy resistance have 
led to the general conception that resistance often arises from the selection of pre-existing rare 
cells that have acquired resistance-conferring genetic alterations (20–22).  In this case, combined 
inhibition of multiple nodes of a single pathway or simultaneous targeting of distinct pathways 
can be effective.  However, recent studies have suggested that non-mutational mechanisms of 
drug resistance are also possible (19,20,23,24), for which intermittent dosing of the same 
inhibitor could induce a re-treatment response (25,26). 
We assessed the requirement of oncogenic KRAS for PDAC maintenance and potential 
resistance mechanisms to KRAS inhibition by analyzing the consequence of acute and sustained 
Kras knockdown in murine PDAC cells in vitro and in vivo.  Additionally, we conducted global 
gene expression and phosphoproteomic profiling of PDAC cells before and after Kras 
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knockdown to decipher mechanisms that mediate escape from Kras oncogene addiction.  
Through these analyses, we defined an adaptive and reversible state of Kras inhibition marked by 
prominent alterations in cell morphology, proliferative kinetics, and cell signaling. Importantly, 
our work revealed candidate targets for rational combination therapies with novel KRAS 
inhibitors in PDAC patients. 
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MATERIALS AND METHODS 
Cell lines and culture conditions 
A, B, and D parental cells were derived from three distinct primary pancreatic tumors 




 mice treated with tamoxifen (Sigma) to induce 
oncogenic Kras
G12D
 activation and biallelic p53 inactivation in the pancreas (13).  Established 
human PDAC cell lines were obtained from the Broad Institute Cancer Cell Line Encyclopedia, 
sourced from DSMZ-Germany (8988T) American Type Culture Collection (ATCC) (PANC-1). 
Identity was authenticated by DNA fingerprinting by the Broad Institute. All cell lines were 
maintained in DMEM (Corning Cellgro) supplemented with 10% fetal bovine serum (Hyclone) 
and penicillin/streptomycin and tested negative for mycoplasma by PCR testing. 
For inducible-shRNA experiments, doxycycline (DOX, Sigma) was used at 1 g/mL in 
culture media and replaced every 2-3 days.  Cell viability was analyzed after 4-5 days of DOX 
treatment using the CellTiter-Glo luminescence assay (Promega), which measures cellular ATP 
levels as a surrogate for cell number and growth.  Luminescence was read on a Tecan M2000 
Infinite Pro plate reader.  Cells were imaged with a Nikon Eclipse TE2000-U light microscope 
and SPOT RT3 camera.  For iTRAQ, cells were grown on 15-cm plates and harvested when 70-
80% confluent for lysis.  For SILAC labeling, cells were passaged in heavy, medium, or light 
media for 7-8 population doublings, and carefully maintained at optimal confluence (70-80%) 
during passaging before lysis. 
 
Inducible shRNA retroviral constructs 
A, B, and D cell lines were sequentially transduced with retroviral constructs for rtTA3 
(MSCV-rtTA3-hygro; Fig. 1A) and constructs for inducible shKras (27) and shLuc expression, 
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adapted from the TGMP (TRE-GFP-miR30-PGK-Puro
R
) inducible knockdown system
previously described by G. Hannon, S. Lowe, and colleagues (28).  8988T and PANC-1 cells 
were transduced with an all-in-one (contains rtTA and TRE-shRNA) inducible knockdown 
lentiviral vectors (pLKO-Tet-ON) containing shLACZ.1650 and shKRAS.407 hairpins, which 
were previously validated (29) and generously provided by Dr. William Hahn. For double 
knockdown experiments, shFAK and shGpr56 were cloned into a TGMB (TRE-GFP-miR30-
PGK-Blast
R
) vector.  mir30-based shRNA 97-mers were synthesized (Life Technologies) for
cloning. The individual shRNAs were cloned into the TGMP and TGMB vectors using XhoI and 
EcoRI restriction enzyme sites.  High-fidelity restriction enzymes and T4 ligase (New England 
BioLabs) were used in recommended buffers.  The sequences of the shRNA 22-mers and primers 
used for shRNA cloning are listed in Supplementary Table 1.  MSCV-IRES-GFP and MSCV-
KrasG12D-IRES-GFP retroviral vectors were used for overexpression studies to confirm on-
target Kras knockdown. 
Retroviral and lentiviral production and transduction 
For retroviral infections, retroviral backbone and pCL-Eco (for mouse cells) were 
transfected into 293T cells with TransIT-LT1 (Mirus Bio).  For lentiviral infections, lentiviral 
backbone, packaging vector (delta8.2 or psPAX2), and envelope (VSV-G) were transfected. 
Supernatant was collected at 48 and 72 hours and applied to target cells with 8 g/mL polybrene 
for transduction.  Transduced cells were treated with 2 g/mL puromycin (Life Technologies), 
400 g/mL hygromycin B (Roche), or 10 g/mL blasticidin S (Life Technologies) for 3-7 days, 
as appropriate, for antibiotic selection.  To generate single cell clones from the transduced cells, 
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we sorted one cell per well into 96-well plates using a FACSAria II (Becton Dickinson) FACS 
sorter. 
In vitro growth and adherence assays 
For growth curves, 250-1000 cells were plated on day 0 and grown for five days in 
culture.  4-5 replicates for each cell line per day were assessed for cell viability by CellTiter-Glo 
(Promega).  Cell viability results were normalized to luminescence at day 0.  For growth curves 
measured in cell number rather than luminescence, 10,000 cells per well were plated in 6-well 
plates on day 0 in three replicates, and cells were trypsinized and counted every day.  Low-
density colony forming assays were performed by plating 1000 cells into 6-well plates in 
triplicate and staining with 0.5% crystal violet 7-10 days after plating. Cells for clonal efficiency 
assay were grown in 96-well dishes for 21 days with media supplementation with or without 
DOX every 2-3 days. Clones were stained with crystal violet and absorbance at 540 nm 
quantified following solubilization with Sorensen’s buffer (0.1M sodium citrate, 50% ethanol, 
pH 4.2).  3D cultures were established by plating 250-500 cells onto a growth factor-reduced 
matrigel (Corning) layer, allowing cell migration into matrigel for 4-6 hours.  Cells were grown 
in complete media for 12 days prior to analysis. For adherence assay, single cell suspensions 
were generated and 5000-10,000 cells were plated in 100 uL media into 96-well plates. After one 
hour, media was aspirated, and cell viability of remaining adhered cells was analyzed by 
CellTiter-Glo and compared to cell viability of suspension cells immediately at time of plating. 
To disrupt actin cytoskeleton, cells were treated with latrunculin B (632 nM) for 1 hour prior to 
imaging. For anoikis assay, cells were grown as single cell suspension for 48 hours on poly-
HEMA (Sigma) coated plates or commercial low-adherence plates (Corning) prior to protein 
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collection for immunoblotting. To determine response to matrigel, suspension cells were 
assessed for cell viability using CellTiter-Glo. 
Immunoblotting 
Cells were lysed with ice-cold RIPA buffer (Pierce), supplemented with 0.5 M EDTA 
and Halt protease and phosphatase inhibitors (Thermo Scientific), rotated at 4
o
C for 15-30
minutes to mix, and centrifuged at maximum speed for 15 minutes to collect whole cell lysates.  
For total pY analysis, cells were lysed by freezing the cell pellet in RIPA buffer (with EDTA and 
inhibitors) at -80
o
C overnight to best preserve phosphorylation.  Protein concentration was
measured with the BCA protein assay (Pierce).  30 g of total protein per sample was loaded into 
4-12% Bis-Tris gradient gels (Life Technologies) and separated by SDS-PAGE.  Proteins were
transferred to nitrocellulose (for fluorescence detection) or PVDF (for chemiluminescent 
detection) membranes.  The following antibodies were used for immunoblotting: mouse anti-
HSP90 (BD #610418, 1:10,000), rabbit anti-β-tubulin (CST 2128, 1:1000), mouse anti-KRAS 
(SCBT sc-30, 1:200), mouse anti-phosphotyrosine (Millipore 4G10, 1:1000), mouse anti-paxillin 
(BD #610052, 1:1000), mouse anti-vinculin (Sigma-Aldrich V9131, 1:800), rabbit anti-FAK 
(Millipore 06-543, 1:1000), rabbit anti-FAK pY397 (Invitrogen 44-624G, 1:1000), rabbit anti-
pERK1/2(T202/Y204) (CST 4370, 1:1000), mouse anti-ERK1/2 (CST 9107, 1:1000), rabbit anti-
CC3(Asp175) (CST 9664, 1:1000), and rabbit anti-cleaved PARP(Asp214) (CST 9541, 1:1000).  
HSP90 and β-tubulin were used as loading controls.  Primary antibodies were detected with 
fluorescent-conjugated (LI-COR) or HRP-conjugated (BioRad) secondary antibodies for 
fluorescent (LI-COR) or chemiluminescent detection (Amersham), respectively. For the 
phospho-RTK array, 500 g protein in 250 l lysis buffer for each sample was incubated with 
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the membrane, and experiment was performed following the protocol provided (R&D Systems 
mouse proteome profiler phospho-RTK array kit #ARY014). 
 
Immunofluorescence 
 For immunofluorescent staining of focal adhesion structures, 50,000 (for D line) or 
100,000 (for B line) cells were plated on cover slips in 6-well plates, and were grown for 2 days 
before paraformaldehyde fixation.  The fixed cells were then stained with mouse anti-paxillin 
(BD #610052, 1:500) or mouse anti-vinculin (Sigma-Aldrich V9131, 1:800), along with DAPI 
(Life Technologies) and Alexa Fluor 555 Phalloidin (ThermoFisher Scientific).  The secondary 
antibody used was donkey anti-mouse IgG (H+L) Alexa Fluor 647 conjugate (ThermoFisher 
Scientific, 1:250).  The stained cells were imagined with Applied Precision DeltaVision Spectris 
Imaging microscope, and images were deconvoluted with the Softworx deconvolution software. 
 
Focal adhesion analysis and quantitation 
Cover slips were coated with 0.1 mg/ml rat tail Collagen I (Corning) diluted in PBS for 1 
hour at 37°C followed by 20 µg/ml Fibronectin (Sigma) diluted in PBS for 1 hour at 37°C.  Cells 
were seeded in a density of 60,000 cells per cover slip.  Cells were fixed 24 hours after seeding 
with 4% PFA in PBS and washed twice in 30mM Glycine/PBS for 5 minutes.  Cells were 
permeabilized using 0.2% Triton/PBS for 5 minutes and subsequently washed with TBST 
followed by blocking in 5% milk powder/TBST for 1 hour at room temperature.  Primary 
antibodies (anti-Vinculin, clone hVin-1, Sigma or anti-Paxillin, clone 349/Paxillin, BD 
Biosciences) were diluted 1:200 in blocking solution and incubated for 45 minutes at 37°C.  
Afterwards, the cells were washed 3x for 5 min with blocking solution and then incubated with 
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secondary antibodies (anti-mouse Alexa594 or anti-rabbit Alexa647, Invitrogen) diluted 1:200 
and Hoechst diluted 1:1000 in blocking solution for 45 minutes at 37°C.  Next, the cells were 
washed 3x for 5 min in TBST, 2x in PBS and once in MilliQ water before mounting.  Cells were 
imaged with an inverted Microscope (TE2000, Nikon) with a 60x Plan Apo 1.40 oil objective 
and a Photometric Coolsnap HQ camera.  
Focal adhesion analysis was performed using ImageJ (Wayne Rasband, National 
Institutes of Health, Bethesda, MD).  Briefly, images were background subtracted using the 
rolling ball method and then thresholded to generate a binary image.  Cell areas without focal 
adhesions were masked manually and the focal adhesions were analyzed using the “Analyze 
Particles” tool and uploaded into the ROI manager.  ROIs were overlaid with the original image 
to check for detection accuracy.  Wrongly detected focal adhesions were deleted and depending 
on the stringency of the thresholding the dilate function was applied to the binary image.  Focal 
adhesion size and numbers were analyzed.  To determine the cell area the cells were outlined and 
the total area was measured.  This measure was used to normalize the number of focal adhesions 
per cell area.  For each condition, eight cells and at least 289 individual focal adhesions were 
analyzed.  
To analyze the percentage of cells with focal adhesions the maximum intensity of all 
images were set to a value of 5,000 and cells were categorized into plus focal adhesions or non-
focal adhesions manually.  12 images per conditions were analyzed. 
 
RNA isolation and RNA-sequencing (RNA-Seq) analysis 
RNA was isolated from PDAC cells using TRIzol (Life Technologies).  cDNA libraries 
were prepared using an Illumina TruSeq sample preparation kit with indexed adaptor sequences 
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and polyA selection.  Sequencing was performed on an Illumina HiSeq 2000 instrument to 
obtain single-end 40-nt reads.  Gene expression data has been deposited into the Gene 
Expression Omnibus (GEO) with accession number GSE95478. All reads that passed quality 
metrics were mapped to the UCSC mm9 mouse genome build (http://genome.ucsc.edu/) using 
RSEM (v1.2.12) (http://deweylab.github.io/RSEM/).  For pairwise differential expression 
analyses, data normalization (MedianNorm) and differential analyses between experimental 
conditions were performed using EBSeq v1.4.0 
(http://bioconductor.org/packages/release/bioc/html/EBSeq.html).  All RNA-Seq analyses were 
conducted in the R Statistical Programming language (http://www.r-project.org/).  Unsupervised 
clustering was performed using a Pearson correlation based pairwise distance measure. Heat 
maps were generated using the Heatplus package in R. 
High-resolution signature analyses between clones within each cell line were performed 
using a blind source separation methodology based on Independent Component Analysis (ICA) 
(30). RSEM generated estimated expression counts were upper-quartile normalized to a count of 
1000.  The R implementation of the core JADE algorithm (Joint Approximate Diagonalization of 
Eigenmatrices) (31) was used along with custom R utilities.  Signatures were visualized using 
the sample-to-signature correspondence schematic afforded by Hinton plots where colors 
represent directionality of gene expression (red relatively upregulated, blue relatively 
downregulated within each signature) and the size of each rectangle quantifies the gene 
expression correlation of a given sample (row) with the gene expression pattern identified by the 
signature (column).  Each signature is two-sided, allowing for identification of upregulated and 
downregulated genes for each signature within each sample.  Biologically relevant and 
statistically significant signatures were identified using a Mann-Whitney U test. 
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For lncRNA analysis reads were mapped to the mouse genome (release NCBIM37) using 
Tophat v2.0.4 and gene annotation from Ensembl (release 66, ensemble.org). Differential 
analyses between Dox and no DOX conditions were performed using Cufflinks v2.0.2. and 
presented in the format detailed in the cufflinks manual (http://cole-trapnell-
lab.github.io/cufflinks/cuffdiff/). 
Gene Set Enrichment Analyses (GSEA) were carried out using the pre-ranked mode 
using log2 fold-change values (for pairwise analyses) or standardized signature correlation 
scores (for ICA signatures) with default settings (32).  Network representations of GSEA results 
were generated using EnrichmentMap (http://www.baderlab.org/Software/EnrichmentMap) for 
Cytoscape v3.3.0 (http://www.cytoscape.org) with p<0.05 and FDR<0.25 as cut-offs.  Each 
circle represents a gene set with circle size corresponding to gene set size and intensity 
corresponding to enrichment significance.  Red is upregulated and blue is downregulated. Each 
line corresponds to minimum 50% mutual overlap with line thickness corresponding to degree of 
overlap. Cellular processes for gene set clusters were manually curated. 
Candidate point mutations in RNA-Seq datasets were called using a pipeline based on the 
GATK Toolkit (https://software.broadinstitute.org/gatk/). Transcriptomic reads were mapped (to 
mm9) using the Tophat (v2.0.4) spliced aligner and subjected to local realignment and score 
recalibration using the GATK Toolkit.  Mutations were called in LT DOX samples (individual) 
against No DOX samples (pooled for individual parental lines) with a minimum base quality 
threshold of 30. Minimum coverage levels of 8X (no-DOX) and 14X (DOX) were required to 
evaluate a locus for mutations. Variants were filtered to retain those with representation on both 
strands. No exonic mutations were found to recur across different pools, and variants found to be 
common between two samples with the same pool did not exceed a 50% variant frequency 
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threshold. The DOX versus no-DOX variant frequency for these within-pool recurrent variants 
did not exceed 31%. Genomic annotations were performed using ANNOVAR 
(http://www.openbioinformatics.org/annovar/). 
Computer code for RNA-Seq independent component analyses is available upon request. 
Other software tools for RNA-Seq analyses, website source, and version numbers are listed 
above. Gene expression data are archived in GEO with accession number GSE95478.   
 
Quantitative RT-PCR 
RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems).  Quantitative PCR (qPCR) was performed using Taqman probes (Applied 
Biosystems).  Ct values were measured by a LightCycler 480 Real-Time PCR System (Roche) 
and relative expression (normalized to TBP or actin) was calculated using the ΔΔCt method. 
 
Drug treatments 
PF562271, PF573228, AZD0530, dasatinib, and SU6656 were purchased from Selleck 
Chemical.  All compounds were diluted to 10 mM stock concentration in DMSO.  To generate 
dose-response curves, cells (250-500 for D clones, 750-1000 for B clones) were plated in 96-well 
white plates (Perkin Elmer) in 100 L of media and incubated overnight.  100 L of drug at 2X 
final concentration was added to each well in triplicate for each cell line and dose.  Cell viability 
was determined at 72 hours using CellTiter-Glo (Promega).  Percent viability was calculated for 
each dosed well compared to solvent controls (DMSO) and plotted against log10[Dose] (M).  
For dose-response curves, each replicate for each cell line and dose was plotted along with 
curve-fit regression for three-component inhibitor response (Prism). 
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Subcutaneous tumor transplant in immunocompromised mice 
All animal studies were approved by the MIT Institutional Animal Care and Use 
Committee.  Cells were transplanted to form tumors in NOD/SCID mice (Taconic) via 
subcutaneous injections.  100 L of cell suspensions of varying concentrations in cold PBS were 
injected per tumor to determine tumor-forming capacity and tumor growth kinetics in the context 
of gene knockdown.  Tumor formation was monitored over time by visual observation. Tumor-
initiating cell number was calculated based on limiting dilutions of transplanted cells using web-
based ELDA software (http://bioinf.wehi.edu.au/software/elda/). 
Tumor growth was followed by caliper measurement or luciferase imaging.  Caliper 
measurement was done in 3-4 day intervals.  Tumor volume was calculated from caliper 
measurements using the modified ellipsoid formula: (length)x(width)
2
/2.  Because the PDAC 
cells are engineered to express MSCV-Luciferase-IRES-GFP (plasmids were retrovirally 
transduced like the inducible shRNA constructs), tumors were measured based on luminescence 
using IVIS spectrum optical imaging (Xenogen corporation).  Bioluminescence imaging by IVIS 
was done in 3-4 day intervals by injecting 100 l of 30 mg/ml luciferin per mouse and imaging 
10 minutes post-injection.  The level of bioluminescence in radiance was analyzed by Living 
Image software (Perkin Elmer).  Cell lines were made from subcutaneous tumors by dissociation 
using a collagenase IV (Worthington), dispase, trypsin, and DNAse cocktail in HEPES-buffered 
HBSS. 
 
Phosphotyrosine analysis via LC-MS/MS (iTRAQ) 
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Cells were lysed in 8 M urea (Sigma) and were quantified using BCA assay (Pierce).  
Proteins were reduced with 10 mM dithiothreitol (Sigma) for 1 hour at 56
o
C and then alkylated 
with 55 mM iodoacetamide (Sigma) for 1h at 25
o
C in the dark.  Proteins were then digested with 
modified trypsin (Promega) at an enzyme/substrate ratio of 1:50 in 100 mM ammonium acetate, 
pH 8.9 at 25
o
C overnight.  Trypsin activity was halted by addition of acetic acid (99.9%, Sigma) 
to a final concentration of 5%.  After desalting using a C18 Sep-Pak Plus cartridge (Waters), 
peptides were lyophilized and store at -80
o
C.  Peptides were labeled with iTRAQ 4plex (AB 
Sciex) as previously described (33).  Lyophilized samples (400 µg) were labeled with 1 aliquot 
of iTRAQ label per peptide sample.  Peptides were dissolved in 30 µL of 500 mM 
triethylammonium bicarbonate, pH 8.5, and each iTRAQ reagent was dissolved in 70µL of 
isopropanol.  Each peptide sample was combined with one of four iTRAQ labels, vortexed, and 
incubated for 1 hour at 25
o
C.  The labeled peptides were then combined and concentrated to 
completion.   
For immunoprecipitation, protein G agarose (60 µL, Millipore) was incubated with anti-
phosphotyrosine antibodies (12 µg 4G10 (Millipore), 12 µg PT66 (Sigma), and 12 µg PY100 
(CST)) in 400 µL of IP buffer (100mM Tris, 100mM NaCl, and 1% Nonidet P-40, pH 7.4) for 8 
hours at 4
o
C with rotation.  The antibody conjugated protein G was washed with 400 µL of IP 
buffer.  The iTRAQ labeled peptides were dissolved in 400 µL IP buffer and the pH was 
adjusted to 7.4.  The iTRAQ labeled peptides were then incubated with the antibody conjugated 
protein G overnight at 4
o
C with rotation.  The agarose was washed with 400 µL IP buffer 
followed by four rinses with 400 µL rinse buffer (100 mM Tris, pH 7.4).  Peptides were eluted 
with 70 µL of 100 mM glycine, pH 2 for 30 minutes at 25
o
C.  Offline immobilized metal affinity 
chromatography (IMAC) was used to further enrich for phosphotyrosine peptides (33).   
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Peptides were then loaded on a pre-column and separated by reverse phase HPLC using 
an EASY- nLC1000 (Thermo) over a 140 minute gradient before nanoelectrospray using a 
QExactive mass spectrometer (Thermo).  The mass spectrometer was operated in a data-
dependent mode.  The parameters for the full scan MS were:  resolution of 70,000 across 350-
2000 m/z, AGC 3e
6
, and maximum IT 50 ms.  The full MS scan was followed by MS/MS for the 
top 10 precursor ions in each cycle with a NCE of 32 and dynamic exclusion of 30 s.  Raw mass 
spectral data files (.raw) were searched using Proteome Discoverer (Thermo) and Mascot version 
2.4.1 (Matrix Science).  Mascot search parameters were:  10 ppm mass tolerance for precursor 
ions; 0.8 Da for fragment ion mass tolerance; 2 missed cleavages of trypsin; fixed modification 
were carbamidomethylation of cysteine and iTRAQ 4plex modification of lysines and peptide N-
termini; variable modifications were methionine oxidation, tyrosine phosphorylation, and 
serine/threonine phosphorylation.  Only peptides with a Mascot score greater than or equal to 25 
and an isolation interference less than or equal to 25 were included in the quantitative data 
analysis.  The average false discovery rate was 0.0029 (ranging from 0.0013-0.0041).  iTRAQ 
quantification was obtained using Proteome Discoverer and isotopically corrected per 
manufacturer’s instructions.  The iTRAQ values were normalized to the mean relative protein 
quantification ratios obtained from a total protein analysis.  For the total protein analysis, 0.2% 
of the supernatant from the phosphotyrosine peptide immunoprecipitation was analyzed via LC-
MS/MS.  This analysis serves as a loading control as it gives quantitation for the most abundant 
non-phosphorylated peptides.  The phosphotyrosine LC-MS/MS analysis was performed three 
times with different sample preparations.  Only tyrosine phosphorylation sites that were detected 
in at least two independent experiments were considered for further analysis.  
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SILAC analysis 
SILAC-labeled cells were cultured at a concentration of 10
6
 cells/mL in DMEM medium 
supplemented with 10% FBS and penicillin/streptomycin, and either normal L-lysine (K0) 
and L-arginine (R0), or medium-labeled D4- lysine (K4) and 
13









N4 arginine (R10).  Lysine and arginine were 
supplemented at concentrations of 40 mg/L and 120 mg/L, respectively.  Labeled murine PDAC 
cells (LT DOX or No DOX) were harvested after 7-8 cell doublings. 
Cells were washed once with PBS and lysed for 30 min in ice-cold lysis urea buffer (8 M 
urea; 75 mM NaCl, 50 mM Tris HCl pH 8.0, 1 mM EDTA, 2 μg/mL aprotinin (Sigma, A6103), 
10 μg/mL leupeptin (Roche, #11017101001), 1 mM PMSF (Sigma, 78830), 10 mM NaF, 5 mM 
sodium butyrate, 5 mM iodoacetamide (Sigma, A3221), Phosphatase Inhibitor Cocktail 2 (1:100, 
Sigma, P5726), Phosphatase Inhibitor Cocktail 3 (1:100, Sigma, P0044).  Lysates were 
centrifuged at 20,000g for 10 min, and protein concentrations of the clarified lysates were 
measured via BCA assay (Pierce, 23227).  A total of 5 mg total proteins per SILAC channel 
were combined for a total of 15 mg proteins per SILAC experiment. 
Protein disulfide bonds of the combined lysates were reduced for 45 min with 5 mM 
dithiothreitol (Thermo Scientific, 20291) and alkylated for 45 min with 10 mM iodoacetamide. 
Samples were then diluted 1:4 with 50 mM Tris HCl, pH 8.0, to reduce the urea concentration to 
2 M. Lysates were digested for 2 h using 1:50 enzyme-to-substrate ratio LysC (Wako, 129-
02541) and trypsin (Promega, V511X) was added in a 1:50 enzyme-to-substrate ratio for digest 
at room temperature overnight. Peptide mixtures were acidified to a final volumetric 
concentration of 1% formic acid (Fluka, 56302) and centrifuged at 2,000g for 5 min to pellet 
urea that had precipitated out of solution.  Peptide mixtures were desalted on tC18 SepPak 
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columns (Waters, 500 mg WAT036790).  Columns were conditioned with 1 × 5 ml 100% 
acetonitrile and 1 × 5 ml 50% acetonitrile/0.1% formic acid washes, and equilibrated with 4 × 5 
ml 0.1% trifluoroacetic acid (Fluka, TX1276-6).  After loading the sample onto the column, 
samples were desalted with 3× 5 ml 0.1% trifluoroacetic acid washes and 1 × 5 ml 1% formic 
acid wash. Peptides were eluted from the column with 2 × 3 ml 50% acetonitrile/0.1% formic 
acid. Eluted peptide samples were placed in a vacuum concentrator to evaporate the elution 
solvent and produce purified peptide samples. 
To reduce peptide complexity, samples were separated by basic reversed-phase 
chromatography.  For basic RP separation, desalted peptides were reconstituted in 1.8 mL 20 
mM ammonium formate, pH 10, and centrifuged at 10,000g to clarify the mixture before it was 
transferred into autosampler tubes.  Basic reversed-phase chromatography was conducted on a 
9.4 mm × 250 mm column Zorbax 300 Å Extend-C18 column (Agilent, 5 μm bead size), using 
an Agilent 1100 Series HPLC instrument.  Solvent A (2% acetonitrile, 5 mM ammonium 
formate, pH 10), and a nonlinear increasing concentration of solvent B (90% acetonitrile, 5 mM 
ammonium formate, pH 10) were used to separate peptides by their hydrophobicity at a high pH.  
We used a flow rate of 3 ml/min and increased the percentage of solvent B in a nonlinear 
gradient with 4 different slopes (0% for 2 min; 0% to 10% in 5 min; 10% to 27% in 34 min; 27% 
to 31% 4 min; 31% to 39% in 4 min; 39% to 60% in 7 min; 60% for 8 min).  Eluted peptides 
were collected in 96 × 2 mL deepwell plates (Whatman, #7701-5200) with 1 min (= 1 ml) 
fractions for the 4.6 mm column and 40 s (= 2 ml) fractions for the 9.4 mm column.  Early 
eluting peptides were collected in fraction “A”, which is a combined sample of all fractions 
collected before any major UV-214 signals were detected. 
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Peptide samples were combined into 24 subfractions, respectively, to be used for 
proteome analysis.  Subfractions were achieved by combining every 24
th
 fraction (1,25,49; 
2,26,50; ...).  Subfractions were acidified to a final concentration of 1% formic acid, and 5% of 
the volumetric samples were reserved for proteome analysis. 
The remaining 95% of each of the original 72 subfractions from bRP (above) were 
further combined before enrichment for PTM analyses as follows: every 12
th
 fraction was 
combined (1,13; 2,14; ...) to generate 12 fractions.  Peptide fractions were subsequently dried by 
vacuum sublimation in a vacuum concentrator.  We have also analyzed an early eluting 
hydrophilic fraction labeled fraction A which contains a large number of multiply 
phosphorylated peptides. 
As described previously (34), iron-chelated IMAC beads were prepared from Ni-NTA 
superflow agarose beads (Qiagen, #1018611) that were stripped of nickel with 100 mM EDTA 
and incubated in an aqueous solution of 10 mM FeCl3 (Sigma, 451649).  Dried phosphopeptide 
fractions were reconstituted in 50% acetonitrile/0.1% trifluoroacetic acid and then diluted 1:1 
with 100% acetonitrile/0.1% trifluoroacetic acid to obtain a final 80% acetonitrile/0.1% TFA 
peptide solution at a concentration of 0.5 μg/μl.  Peptide mixtures were enriched for 
phosphorylated peptides with 10 μL IMAC beads for each sample for 30 min.  Enriched IMAC 
beads were loaded on Empore C18 silica-packed stage tips (3M, 2315).  Stage tips were 
equilibrated with 2 × 100 μL washes of methanol, 2 × 50 μL washes of 50% acetonitrile/0.1% 
formic acid, and 2 × 100 μL washes of 1% formic acid.  Samples were then loaded onto stage 
tips and washed twice with 50 μL of 80% acetonitrile/0.1% trifluoroacetic acid and 100 μL of 
1% formic acid.  Phosphorylated peptides were eluted from IMAC beads with 3 × 70 μL washes 
of 500 mM dibasic sodium phosphate, pH 7.0, (Sigma, S9763) and washed twice with 100 μL of 
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1% formic acid before being eluted from stage tips with 60 μL 50% acetonitrile/0.1% formic 
acid.  All washes were performed on a tabletop centrifuge at a maximum speed of 3,500g. 
All peptide samples were separated on an online nanoflow EASY-nLC 1000 UHPLC 
system (Thermo Fisher Scientific) and analyzed on a benchtop Orbitrap Q Exactive mass 
spectrometer (Thermo Fisher Scientific).  Ten percent of each proteome (containing ~1 μg) and 
fifty percent of each phosphopeptide, K(GG) peptide, and K(Ac) peptide sample were injected 
onto a capillary column (Picofrit with 10 μm tip opening / 75 μm diameter, New Objective, 
PF360-75-10-N-5) packed in-house with 20 cm C18 silica material (1.9 μm ReproSil-Pur C18-
AQ medium, Dr. Maisch GmbH, r119.aq).  The UHPLC setup was connected with a custom-fit 
microadapting tee (360 μm, IDEX Health & Science, UH-753), and capillary columns were 
heated to 50 °C in column heater sleeves (Phoenix-ST) to reduce backpressure during UHPLC 
separation. Injected peptides were separated at a flow rate of 200 nL/min with a linear 80 min 
gradient from 100% solvent A (3% acetonitrile, 0.1% formic acid) to 30% solvent B (90% 
acetonitrile, 0.1% formic acid), followed by a linear 6 min gradient from 30% solvent B to 90% 
solvent B.  Each sample was run for 150 min, including sample loading and column equilibration 
times.  Data-dependent acquisition was obtained using Xcalibur 2.2 software in positive ion 
mode at a spray voltage of 2.00 kV.  MS1 Spectra were measured with a resolution of 70,000, an 
AGC target of 3e6 and a mass range from 300 to 1800 m/z.  Up to 12 MS2 spectra per duty cycle 
were triggered at a resolution of 17,500, an AGC target of 5e4, an isolation window of 2.5 m/z 
and a normalized collision energy of 25.  Peptides that triggered MS2 scans were dynamically 
excluded from further MS2 scans for 20 s. 
All mass spectra were analyzed with MaxQuant software version 1.3.0.5 using a mouse 
UniProt database.  MS/MS searches for the proteome data sets were performed with the 
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following parameters: Oxidation of methionine and protein N-terminal acetylation as variable 
modifications; carbamidomethylation as fixed modification.  For IMAC data sets 
phosphorylation of serine, threonine and tyrosine residues were searched as additional variable 
modifications.  Trypsin/P was selected as the digestion enzyme, and a maximum of 3 labeled 
amino acids and 2 missed cleavages per peptide were allowed.  The mass tolerance for precursor 
ions was set to 20 p.p.m. for the first search (used for nonlinear mass re-calibration) and 6 p.p.m. 
for the main search.  Fragment ion mass tolerance was set to 20 p.p.m.  For identification we 
applied a maximum FDR of 1% separately on protein, peptide and PTM-site level.  We required 
2 or more unique/razor peptides for protein identification and a ratio count of 2 or more for 
protein quantification per replicate measurement.  PTM-sites were considered to be fully 
localized when they were measured with a localization probability >0.75 in each of the three 
replicates.  To assign regulated proteins and PTM-sites we used the Limma package in the R 
environment to calculate moderated t-test Pvalues corrected by the Benjamini Hochberg method, 
as described previously
48
.  Bland-Altman filtering was applied at 99.9% (+/-3.29 sigma). 
 
Combined analysis of SILAC and iTRAQ data 
To ensure the identification of critical pathways that mediate the response to Kras 
inhibition with minimal clonal or technical confounding effects, we only included peptides that 
were called in at least two replicates of iTRAQ experiments and showed significant correlation 
in the up and down-regulated genes (≥2-fold for SILAC, ≥1.2-fold for iTRAQ) in the Kras-
inhibited cells in both clones (p<0.0001, Pearson correlation). 
 
Statistical analyses 
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P-values for comparisons of two groups were determined by two-tailed Student’s t-test (for 
normally distributed data) or Mann-Whitney U-test (for non-parametric data), as noted in the 
figure legends. Chi-square analysis was performed for statistical evaluation of clonal efficiency. 
Pearson correlations were calculated for scatter plots of phosphoproteomic and proteomic data 
(Prism). All replicates were included in these analyses. A p-value of <0.05 was used to denote 
statistical significance. All error bars denote 95% confidence intervals, standard error of mean 
(s.e.m.), or standard deviation (s.d.), as noted in the figure legends. 
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RESULTS 
Temporal control of endogenous Kras expression in PDAC cells 
 To elucidate the consequence of inhibiting endogenous Kras in PDAC, we first derived 
cell lines from three distinct primary tumors (labelled A, B, and D) from an autochthonous 




), which recapitulates the biology of 
human PDAC (13).  We used murine cells with defined genetic alterations frequently observed 
in human PDACs (Kras and p53) (6,35) to minimize genetic variability in our analyses.  We 
transduced these cell lines with a doxycycline-inducible shRNA-mediated knockdown system 
that enables the temporal control of endogenous Kras expression (Fig. 1A and Supplementary 
Table 1).  Here, partial inhibition and the subsequent reactivation of endogenous Kras are 
achieved by administration and withdrawal of doxycycline (DOX).  We employed two DOX-
inducible miR30-based hairpins targeting the 3’-UTR of Kras (shKras.1442 or shKras.923) or a 
control hairpin targeting firefly luciferase (shLuc).  These Kras hairpins do not distinguish 
between wild-type and mutant alleles of Kras due to 3’-UTR targeting.  Following retroviral 
transduction, we selected for cells with robust hairpin expression by 24-48 hours of DOX 
treatment (prior to visible phenotypic consequences of Kras knockdown) to induce concomitant 
expression of a GFP reporter and the hairpin, and isolated single cell clones that express GFP at 
the highest levels by FACS.  Finally, we confirmed on-target Kras protein and mRNA 
knockdown at >70% in these clones under DOX treatment (Figs. 1B-C, Supplementary Figs. 
1A-C).  
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Murine PDAC cells tolerate stable Kras knockdown in vitro and in vivo 
Rather than undergoing permanent growth arrest or apoptosis, all PDAC cells analyzed 
tolerated acute and sustained Kras knockdown and continued to proliferate in vitro.  Short-term 
DOX treatment for 3-5 days (“ST DOX”) of shKras-expressing cells, but not shLuc-expressing 
cells, resulted in significantly altered cell morphology and decreased proliferation, consistent 
with a partial requirement of endogenous Kras expression for PDAC maintenance (Figs. 1D-E).  
Under prolonged DOX treatment for >21 days (“LT DOX”), shKras-expressing cells retained 
GFP and shKras hairpin expression, and demonstrated persistent Kras knockdown (Figs. 1B-C).  
LT DOX cells continued to proliferate with slower kinetics than untreated cells (“No DOX”) and 
maintained morphological changes (Figs. 1E-F).  
To examine the requirement of endogenous Kras for PDAC maintenance in vivo, we 
transplanted untreated shKras-transduced cells subcutaneously into nude mice, allowed tumors to 
form, and induced hairpin expression with DOX food.  Acute Kras knockdown in established 
tumors resulted in decreased tumor growth and even tumor regression, attributable in part to 
decreased proliferation as evident by reduced BrdU incorporation (Supplementary Figs. 2A-C).  
Despite long-term DOX treatment of mice (>6 weeks; LT DOX), tumors grew at decreased rates 
compared to untreated tumors and retained GFP expression (Supplementary Fig. 2D).  Taken 
together, these observations suggest that endogenous levels of Kras expression are not essential 
for maintaining murine PDAC cell proliferation and survival in vitro or in vivo. 
 
Response to Kras knockdown is adaptive and reversible 
It is generally thought that cancer cells gain resistance to oncogene inhibition through 
elimination of a sensitive cell population and outgrowth of a resistant population.  Given the lack 
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of significant apoptosis with acute and sustained Kras knockdown and the rapid conversion of 
cell morphology, we hypothesized that murine PDAC cells underwent adaptation to a state 
tolerant to Kras inhibition rather than selection of rare cells intrinsically resistant to Kras 
knockdown.  To distinguish between these two possibilities, we analyzed the number of single 
cell clones that could grow from shKras-transduced cell lines in the absence or presence of 
sustained DOX treatment.  If there were a selection process, we would expect to see a marked 
decrease in the number of clones that formed under prolonged DOX treatment.  Alternatively, if 
adaptation occurred, then the same number of clones should form regardless of DOX treatment 
condition.  While we observed differences between parental cell lines, the vast majority of clones 
were able to expand despite sustained Kras knockdown (Fig. 2A), suggesting adaptation to a 
state tolerant to Kras inhibition (Kras-inhibited state).  All colonies that did form in DOX were 
smaller in size, consistent with the expected decreased proliferative rate following Kras 
knockdown (Fig. 2B).  Indeed, when we removed DOX to restore Kras levels (Fig. 2C), cells 
rapidly reverted morphological phenotypes and proliferative kinetics (Figs. 2D-E).  Finally, cells 
were re-sensitized to DOX treatment in terms of proliferative and morphological phenotypes 
(Fig. 2F).  Collectively, these observations indicate that murine PDAC cells respond to partial 
Kras inhibition by a reversible cell state change. 
 
Diminished in vivo tumor initiating capacity following stable Kras inhibition 
While Kras inhibition did not significantly block the ability of PDAC clones to form in 
2D cultures (Fig. 2A), we also interrogated the tumorigenic ability of Kras-inhibited cells in 3D 
culture in vitro and in immunocompromised mice in vivo, as Kras has been implicated in 
maintaining tumor-initiating cells (TICs) or stemness (36).  Interestingly, Kras-inhibited cells 
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retained the ability to form 3D tumorspheres in matrigel in vitro (Fig. 3A) in similar relative 
frequencies to 2D clonal cultures (Fig. 2A), though the spheres that formed were smaller, 
consistent with a proliferative defect (Fig. 3B).  In contrast, Kras-inhibited cells exhibited 
reduced TICs in forming subcutaneous tumors in vivo (Fig. 3C and Supplementary Table 2).  
However, tumors did form from LT DOX-treated shKras-expressing cells.  Sustained Kras 
inhibition was maintained even in secondary cell lines (Fig. 3D), which exhibited comparable 
levels of Kras protein and mRNA knockdown to that of the primary cell lines (Fig. 3E-F).  
Collectively, these data suggest that sustained Kras inhibition can reduce cell proliferation in 
vitro and in vivo and impair TICs in vivo, confirming that Kras is a valuable therapeutic target.  
Nonetheless, Kras inhibition did not ablate the tumorigenic ability of murine PDAC cells. 
 
The Kras-inhibited state does not display significant alterations in gene expression 
 We next sought to understand the molecular and biochemical changes associated with the 
Kras-inhibited state, which may reveal targetable mechanisms of resistance.  To identify 
transcriptional changes associated with adaptation to this state, we performed RNA-sequencing 
on polyA-selected RNA from six shKras-transduced Kras-inhibited and -uninhibited subclone 
pairs (2 per primary cell line A, B, and D) and a control shLuc-transduced pair.  We verified data 
quality by confirming Kras knockdown and identifying the engineered CT G12D Kras gene 
mutation in the transcript sequencing reads.  We did not identify recurrent non-synonymous 
mutations in exonic regions in the Kras-inhibited cells (Supplementary Table 3).  Strikingly, 
we also did not observe significant differences in coding gene or lncRNA expression between the 
baseline and Kras-inhibited states (Supplementary Tables 4 and 5).  Indeed, unsupervised 
hierarchical clustering demonstrated that gene expression differences were driven more strongly 
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by parental cell line and subclonal identity rather than alterations in the Kras expression state 
(Fig. 4A).  
To account for clonal variability and to derive a robust gene signature associated with the 
Kras-inhibited state using an unbiased approach, we employed a blind-source separation method 
termed independent component analysis (ICA).  This separation technique not only derived gene 
expression signatures associated with individual parental cell lines or clones, but also identified 
signature profiles that distinguished the independent gene expression changes associated with 
Kras knockdown and DOX treatment (using the shLuc control cell line treated with DOX) (Figs. 
4B-D).  It became readily apparent that DOX treatment alone could have significant effects on 
gene expression independent of Kras knockdown in our cell lines.  For example, the G-protein 
coupled receptor Gpr56 was strongly upregulated by DOX (Supplementary Table 3) and was 
significantly associated with the DOX signature but not the Kras knockdown signature (z-scores 
of 7.32 and -0.51, respectively).  We confirmed that Gpr56 represented an endogenous 
eukaryotic target of the prokaryotic protein rtTA in the presence of DOX (Supplementary Figs. 
3A-C).  As expected, Gpr56 knockdown did not impact the proliferative or morphological 
phenotypes of Kras-inhibited cells (Supplementary Figs. 3D-E).  This ability to distinguish a 
DOX-regulated gene from a Kras-regulated gene demonstrates the power of ICA to identify 
functionally important gene signatures.  Furthermore, genes in the Kras knockdown signature 
were specifically and significantly, although not strongly, enriched in Kras-inhibited cells (Fig. 
4D).  Comparison of the degree of transcriptional alterations associated with either DOX 
treatment or Kras knockdown suggested that stable Kras inhibition does not lead to striking gene 
expression changes (Figs. 4C-D), contrary to what one might expect as Kras-mediated signal 
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transduction ultimately regulates nuclear transcriptional activity.  These observations suggest 
that the Kras-inhibited state is not strongly dependent on mutational or transcriptional alterations. 
To elucidate potential Kras-regulated transcriptional pathways or functionally important 
pathways that maintain cell viability in the Kras-inhibited state, we performed gene set 
enrichment analysis (GSEA) on the Kras knockdown signature.  While few genes sets in 
MSigDB were significantly associated with the Kras knockdown signature, network correlation 
analysis revealed enrichment of gene sets associated with receptor tyrosine kinase (RTK), 
PI3K/AKT signaling, receptor endocytosis and recycling, and redox metabolism in Kras-
inhibited cells (Fig. 4E), possibly because these compensatory pathways are upregulated in 
response to Kras inhibition to support the steady-state proliferation of PDAC cells. 
 
Global phosphoproteomic profiling reveals enhanced focal adhesion signaling in the Kras-
inhibited state 
 We hypothesized that signaling flux through alternative pro-proliferation and pro-
survival pathways may underlie the adaptive state.  Importantly, identification of compensatory 
pathways could uncover potentially druggable protein targets for PDAC therapy.  We first 
examined signaling differences between the Kras-uninhibited and -inhibited states in a tyrosine-
focused fashion, because the best-characterized upstream regulators of Kras-mediated signal 
transduction are RTKs and genes associated with RTK signaling are enriched in the Kras 
knockdown signature (Fig. 4E).  Assessment of global tyrosine phosphorylation levels (Fig. 5A) 
showed an overall increase in the levels of tyrosine phosphorylation in Kras-inhibited cells, 
suggestive of increased activation of tyrosine kinase-mediated pathways that may compensate 
for decreased Kras levels.  However, a limited phospho-RTK array did not reveal candidate 
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upstream regulators mediating the adaptive state change (Supplementary Fig. 4A).  Therefore, 
we employed two distinct approaches for unbiased global phosphoproteomic analysis: stable 
isotope labeling by amino acids in cell culture (SILAC) and isobaric tag for relative and absolute 
quantitation (iTRAQ).  The SILAC approach (34) enables analysis of serine-, threonine-, and 
tyrosine-phosphorylated peptides (pS, pT, and pY, respectively) as well as total proteome 
changes. As a complementary approach, we adopted an optimized iTRAQ protocol to enrich 
specifically for the lowly abundant tyrosine-phosphorylated peptides (33), enhancing the 
resolution of tyrosine kinase signaling analysis of the Kras-inhibited state (Supplementary Fig. 
4B).  Combining these two approaches, we cross-compared candidate signaling pathways 
specifically activated or inhibited in the Kras-inhibited state. 
Total proteome differences between Kras-uninhibited and Kras-inhibited states showed 
minimal overall protein abundance alterations by SILAC (Supplementary Figs. 5A-B and 
Supplementary Table 6), consistent with the paucity of transcriptional changes.  Importantly, 
one of the few proteins whose abundance was significantly altered in the Kras-inhibited state was 
Kras itself (reduced by 60%).  Conversely, the highest upregulated protein was the DOX-
inducible gene Gpr56. For iTRAQ, each experimental replicate identified a robust number of pY 
peptides that were called with stringent criteria, and at least 230 overlapping pY peptides were 
identified in more than two replicates (Fig. 5B and Supplementary Tables 7-9).  Additionally, 
the signaling changes that occurred in the two independent evaluated clones, B (B shKras.1442 
cl2) and D (D shKras.923 cl1), exhibited reasonable correlation (Figs. 5C-D), suggesting that the 
clonal and parental cell line differences were small. 
We next performed combined analysis of phosphoprotein abundance from SILAC and 
iTRAQ data, and found that multiple sites on focal adhesion-associated proteins showed 
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increased phosphorylation (Fig. 5C).  Examples included Src, focal adhesion kinase (FAK), 
tensin, paxillin, talin, and vinculin, among many others (Fig. 5C).  Furthermore, despite the low 
abundance of pY residues in the total phosphoproteome, our SILAC analysis identified 20-30 pY 
peptides that overlapped with iTRAQ analysis (Supplementary Fig. 5C).  Phosphosites on 
proteins associated with adhesion pathways also exhibited significant upregulation in the SILAC 
analysis (Fig. 5D and Supplementary Table 10).  Collectively, these signaling changes suggest 
that the Kras-inhibited state is characterized by enhanced focal adhesion signaling. Accordingly, 
immunofluorescent staining for the focal adhesion protein vinculin confirmed markedly 
enhanced focal adhesion structures in Kras-inhibited cells (Figs. 6A-C).  Therefore, a major 
feature of the Kras-inhibited state is the upregulation of focal adhesion pathway signaling. 
 
The Kras-inhibited state depends on cell attachment 
Given enhanced focal adhesion signaling and structures in Kras-inhibited cells, we 
hypothesized that Kras-inhibited cells are more dependent on attachment for survival. Kras-
inhibited cells exhibited enhanced cell attachment capacity, demonstrated by faster adherence to 
culture dishes than uninhibited cells (Fig. 6D).  This property likely underlies the greater 
resistance of Kras-inhibited cells to actin polymerization inhibitor latrunculin B-induced 
detachment (Fig. 6E).  Moreover, Kras-inhibited cells were more sensitive to anoikis, as evident 
by increased induction of apoptosis in non-adherent culture conditions (Fig. 6F).  Conversely, 
Kras-inhibited cells exhibited significantly enhanced viability in suspension when the media was 
supplemented with extracellular matrix proteins (Fig. 6G).  Overall, analyses of the cell 
biological features of Kras-inhibited cells reveal enhanced adherence properties and an increased 
dependency on adhesion for cell viability in vitro. 
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To determine the relevance of our findings to human PDAC, we introduced DOX-
inducible hairpins targeting LACZ (control) or KRAS into 8988T and PANC1 human PDAC cell 
lines, which we and others have previously shown tolerate KRAS inhibition (15,16,37).  
Consistent with observations in murine cells, KRAS knockdown in human PDAC cell lines (Fig. 
7A, Supplementary Fig. 6A) resulted in morphological changes and decreased proliferation that 
were reversible by KRAS reactivation (Figs. 7B-D, Supplementary Figs. 6B-D).  Additionally, 
8988T cells in the KRAS-inhibited state exhibited increased sensitivity to anoikis (Fig. 7E) and 
enhanced focal adhesion structures (Figs. 7D, 7F, and 7G), indicative of dependency on cell 
attachment. While KRAS-inhibited PANC1 cells did not display increased anoikis sensitivity 
(Supplementary Fig. 6E), they showed enhanced focal adhesion structures (Supplementary 
Figs. 6D, 6F, and 6G).  The variability in response on focal adhesion formation and dependence 
observed in human PDAC cells compared to the murine models likely emerge from the greater 
heterogeneity (e.g. genetic, phenotypic) seen in human PDAC.  Nonetheless, these results reveal 
that our findings in murine PDAC cells are relevant to at least a subset of human PDAC cells. 
 
Genetic or pharmacological inhibition of FAK does not impair survival of Kras-inhibited 
PDAC cells 
We hypothesized that direct inhibition of focal adhesion kinase (FAK) may target a 
unique vulnerability in the context of Kras inhibition, and interrogated the requirement of FAK-
mediated signaling in maintaining Kras-inhibited cell viability. Kras-inhibited cells did not show 
increased sensitivity compared to uninhibited cells to pharmacological inhibition of FAK or the 
central upstream regulator of the focal adhesion signaling pathway Src (Supplementary Fig. 7).  
As both FAK and Src integrate multiple signaling pathways and the off-target effects of 
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pharmacological inhibitors could mask differential sensitivity, we performed more-specific 
shRNA-mediated knockdown of FAK (Supplementary Fig. 8A).  Even though FAK 
knockdown disrupted the polarity and organization of focal adhesion plaques, it did not ablate 
the formation of these structures in Kras-inhibited cells (Supplementary Fig. 8B).  Moreover, 
FAK knockdown did not synergize with Kras knockdown to further impair proliferation in vitro 
or subcutaneously transplanted tumor growth in vivo (Supplementary Fig. 8C and 
Supplementary Figs. 9A-E).  These data suggest that there may be compensatory mechanisms 
to maintain focal adhesions upon FAK inhibition.  While FAK inhibition was insufficient to 
impair Kras-inhibited cell survival, blockade of the cell adhesion phenotype through alternative 
means may still offer a tractable therapeutic strategy. 
DISCUSSION 
We interrogated the requirement of endogenous Kras for maintaining murine PDAC cell 
survival with an inducible shRNA-based knockdown system.  Surprisingly, our results 
demonstrated only a partial requirement of Kras for PDAC maintenance.  Not only were PDAC 
cells able to proliferate under sustained Kras knockdown, but they also retained oncogenic 
capabilities in vitro and in vivo.  The majority of murine PDAC cells tolerated acute and 
sustained Kras inhibition by adapting to a reversible state.  The lack of significant mutational and 
gene expression changes indicated that such resistance to Kras inhibition was non-genetic and 
non-transcriptional.  Global phosphoproteomic analyses confirmed that the Kras-inhibited state 
was a result of rewiring of signaling through alternative pathways.  Specifically, Kras-inhibited 
PDAC cells exhibited upregulation of focal adhesion signaling and enhanced adherence 
properties and dependence.  Due to possible compensatory mechanisms, inhibition of FAK or 
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Src alone was insufficient to selectively impair Kras-inhibited cell survival.  Nevertheless, 
components of this pathway could be novel drug targets for rational combination therapies. 
Unlike its well-established role as the driver of PDAC initiation, whether endogenous 
oncogenic Kras is required for PDAC maintenance has remained a longstanding question.  To 
elucidate the dependency of PDAC cells on Kras for survival, we employed an in vitro system 
that allows reversible Kras knockdown to mimic the effect of a non-specific pharmacological 
Kras inhibitor.  It is possible that mutant Kras-specific inhibition could have differential effects 
from combined inhibition of both alleles, since wild-type Kras has been shown to act as either a 
tumor suppressor (38) or oncogenic driver (i.e. through amplification) (39–41) in different cancer 
types.  However, the vast majority of approaches currently being developed to inhibit KRAS are 
not allele-specific (8), thus our system can be utilized to predict mechanisms of resistance to 
these inhibitors.  
Our approach has several advantages over previous work to understand the requirement 
of Kras for PDAC maintenance and potential mechanisms of resistance to Kras inhibition.  Early 
studies used constitutive RNAi to knockdown Kras in human PDAC cell lines and correlate 
dependency with gene expression.  These experiments defined human PDAC cell lines with 
variable dependencies on Kras for survival following short-term inhibition, but the effects of 
sustained knockdown, as would more closely mimic treatment of patients, were undefined 
(15,16).  More recent work used a doxycycline-inducible RNAi approach to knockdown Kras in 
human PDAC cell lines and established human tumor xenotransplants.  While comparable 
decreased in vitro proliferation and slower tumor growth in vivo were observed, signaling studies 
were limited to the study of well-defined MAPK and PI3K pathways (42).  Recent in vivo studies 
aimed to characterize the requirement of sustained oncogenic Kras expression for pancreatic 
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
 35 
cancer maintenance have employed elegant mouse models engineered to express an inducible 
oncogenic Kras transgene (9,11,12).  Because oncogenic Kras alone induces PDAC with low 
frequency and long latency, these models require additional tumor suppressor inactivation or 
pancreatitis induction to facilitate PDAC development.  In these models, withdrawal of 
oncogenic Kras transgene expression in established PDAC tumors led to an initial tumor 
regression due to apoptosis, but tumor relapse was observed after a period of dormancy 
(9,11,12,17,18).  While these studies provide invaluable insights into the requirement of 
oncogenic Kras for tumor maintenance, care must be taken into extrapolating the effects of 
overexpression of an oncogenic Kras transgene to explain its endogenous functions.  Finally, 
CRISPR-mediated ablation of endogenous Kras in human and murine PDAC cells demonstrated 
that Kras is dispensable for survival in a subset of PDAC cells, and that Kras-deficient cells 
exhibited increased dependency on PI3K signaling (37).  However, achieving complete 
pharmacological inhibition of KRAS is challenging.  Furthermore, CRISPR-mediated knockout 
is irreversible, impairing the ability to distinguish between clonal selection and adaptation as 
modes of resistance.   
Consistent with results from these previous studies, we found that PDAC cells can bypass 
Kras oncogene addiction by adapting to a reversible Kras-inhibited state.  Conventionally, it is 
thought that resistance to cancer therapies occurs by selection of rare cells.  Our observations 
support the emerging view that non-genetic resistance mechanisms can be equally relevant 
(19,20).  Given the significant investment into the development of KRAS inhibitors, advanced 
knowledge of these resistance mechanisms would facilitate the clinical translation of novel 
inhibitors and overcome the limitations of single-agent therapy. 
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Unbiased phosphoproteomic analyses of the Kras-inhibited state uncovered increased 
focal adhesion signaling as a possible resistance mechanism to Kras inhibition.  This intriguing 
finding led us to explore the benefit of targeting FAK in Kras-inhibited PDAC cells.  FAK is the 
central kinase of focal adhesion signaling, and is known to integrate adhesion- and growth 
factor-dependent signals to regulate cell adhesion, motility, and survival (43,44).  Interestingly, 
FAK overexpression in human cancers is often associated with worse prognosis (45,46).  
Furthermore, FAK interacts with multiple regulators and effectors of KRAS.  It has been 
suggested that KRAS-mediated activation of MEK1 results in phosphorylation of FAK at 
Ser910, which decreases FAK kinase activity (47).  Moreover, FAK inhibition has been shown 
to suppress the growth of xenograft PDAC tumors with gemcitabine treatment (48).  Together, 
the connection between FAK and KRAS-mediated signaling as well as its implication in human 
cancers made FAK an appealing target.  Unfortunately, as focal adhesion signaling involves 
multiple inputs and outputs, FAK inhibition alone was insufficient to impair Kras-inhibited cell 
survival.  Nevertheless, identification of the critical nodes of focal adhesion signaling that 
underlie resistance to KRAS inhibition may inform rational therapeutic combinations with novel 
KRAS inhibitors. 
In summary, we have employed a conditional RNAi system to study the requirement of 
endogenous Kras in PDAC maintenance, and performed unbiased gene expression and 
phosphoproteomic analyses to characterize the adaptive and reversible Kras-inhibited state.  Our 
observations have important therapeutic implications.  First, by showing that the majority of cells 
could tolerate an approximately 70% inhibition of Kras, it is possible that a KRAS-directed 
inhibitor needs to achieve near-complete inhibition of KRAS function to exhibit significant 
clinical impact.  Alternatively, multiple nodes of KRAS signaling may need to be inhibited to 
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achieve greater efficacy.  Second, even if an effective KRAS inhibitor is successfully developed, 
resistance may develop.  Since PDAC cells can circumvent Kras inhibition via an adaptive and 
reversible state change, intermittent dosing of a KRAS-directed inhibitor to allow for re-
treatment response may be beneficial.  Finally, the Kras-inhibited state is characterized by 
signaling alterations, so targeting compensatory pathways with KRAS inhibition could be a 
useful therapeutic strategy. 
ACKNOWLEDGEMENTS 
We thank K. Mercer, J. Singh, E. Vasile and D. Riquelme for technical assistance; F. 
White, M. Yaffe, B. Joughin, and K. Krismer for assistance with phosphoproteomic analyses; W. 
Xue, H. Jenq, and S.G. Friedlander for advice and reagents; G. Hannon, W. Hahn, and S. Lowe 
for constructs; and A. Berns and D. Melton for mice. 
This work was supported by an NCI K08 Award (M.D.M.), KL2/Catalyst MeRIT award 
(M.D.M.), CCF/ASCO Young Investigator Award (M.D.M.), the Howard Hughes Medical 
Institute (T.J.), Lustgarten Foundation Consortium grant (T.J.), Blum-Kovler Pancreatic Cancer 
Action Network-AACR Innovative grant (T.J.), Department of Defense Congressionally-
Directed Medical Research Program grant (W81XWH-12-043) (T.J.), and in part by the Cancer 
Center Support (core) grant P30-CA14051 from the National Cancer Institute.   
P-Y.C., M.D.M., and T.J. designed the study; P-Y.C., M.D.M., K.J.D., R.R., A.R., P.M,
J.Q., and A.C.S. performed experiments; A.B. conducted bioinformatics analyses; P-Y.C.,
M.D.M., and T.J. wrote the manuscript.
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
 38 
REFERENCES 
1.  Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. NEJM. 2014;371:1039–49.  
2.  American Cancer Society. Cancer Facts and Figures 2017. 2017;Atlanta: A.  
3.  Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. 
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 
2011;364:1817–25.  
4.  Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased 
Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 
2013;369:1691–703.  
5.  Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core signaling 
pathways in human pancreatic cancers revealed by global genomic analyses. Science. 
2008;321:1801–6.  
6.  Waddell N, Pajic M, Patch A, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes 
redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.  
7.  Bardeesy N, DePinho R. Pancreatic cancer biology and genetics. Nat Rev Cancer. 
2002;2:897–909.  
8.  Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: 
Mission Possible? Nat Rev Drug Discov. Nature Publishing Group; 2014;13:828–51.  
9.  Collins MA, Bednar F, Zhang Y, Brisset J, Galbán S, Galbán CJ, et al. Oncogenic Kras is 
required for both the initiation and maintenance of pancreatic cancer in mice. J Clin 
Invest. 2012;122:639–53.  
10.  Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. 
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely 
metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.  
11.  Ying H, Kimmelman AC, Lyssiotis C a., Hua S, Chu GC, Fletcher-Sananikone E, et al. 
Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose 
metabolism. Cell. Elsevier Inc.; 2012;149:656–70.  
12.  Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, et al. Metastatic 
Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice. PLoS One. 2012;7.  
13.  Friedlander SYG, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, et al. Context-
Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. Cancer Cell. 
2009;16:379–89.  
14.  Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz M a., et al. 
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. 
Cancer Cell. 2003;4:437–50.  
15.  Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A Gene 
Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and 
Tumor Cell Survival. Cancer Cell. Elsevier Ltd; 2009;15:489–500.  
16.  Collisson E a, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of 
pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
39 
Nature Publishing Group; 2011;17:500–3. 
17. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables
bypass of oncogenic KRAS addiction in pancreatic cancer. Cell. Elsevier Inc.;
2014;158:185–97.
18. Viale A, Pettazzoni P, Lyssiotis C a., Ying H, Sánchez N, Marchesini M, et al. Oncogene
ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature.
2014;514:628–32.
19. Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, et al. Reversible and
adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. Nature Publishing
Group; 2014;508:118–22.
20. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et
al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal
growth factor receptor inhibition. Nat Med. 2016;22:262–9.
21. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug
resistance. Mol. Oncol. 2014. page 1095–111.
22. Pribluda A, de la Cruz C, Jackson E. Intratumoral Heterogeneity: From Diversity Comes
Resistance. Clin Cancer Res. 2015;21:2916–23.
23. Sharma S V., Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A
Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell.
Elsevier Ltd; 2010;141:69–80.
24. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic
clinical drug resistance. Br J Cancer. 2006;94:1087–92.
25. Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai G, Nakagawa K FM. Effect
of re-treatment with gefitinib (“Iressa”, ZD1839) after acquisition of resistance. Ann
Oncol. 2004;15:173–177.
26. Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, Edakuni N, Kakiuchi S,
Nishikubo N, Muguruma H SS. Retreatment of lung adenocarcinoma patients with
gefitinib who had experienced favorable results from their initial treatment with this
selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res.
2005;15:107–11.
27. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1
converge to regulate EMT and tumor survival. Cell. Elsevier; 2014;158:171–84.
28. Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, et al. A rapid and
scalable system for studying gene function in mice using conditional RNA interference.
Cell. 2011;145:145–58.
29. Barbie D a, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA
interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature.
2009;462:108–12.
30. Hyvarinen A, Oja E. Independent component analysis: algorithms and applications.
Neural Networks. 2000;13:411–30.
31. Rutledge DN, Jouan-Rimbaud Bouveresse D. Independent Components Analysis with the
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
 40 
JADE algorithm. Trends Anal Chem. Elsevier Ltd; 2013;50:22–32.  
32.  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL. Gene set enrichment 
analysis : A knowledge-based approach for interpreting genome-wide. Proc Natl Acad Sci 
U S A. 2005;102:15545–15550.  
33.  Zhang Y, Wolf-yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, et al. Time-
resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth 
factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics. 
2005;4:1240–50.  
34.  Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, et al. Integrated 
proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 
2013;10:634–7.  
35.  Bailey P, Chang DK, Nones K, Johns AL, Patch A, Gingras M, et al. Genomic analyses 
identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.  
36.  Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, et al. K-Ras 
Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell. 
2015;163:1237–51.  
37.  Muzumdar MD, Chen P, Dorans KJ, Chung KM, Bhutkar A, Hong E, et al. Survival of 
pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;1090:1–19.  
38.  Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, et al. Wildtype Kras2 can inhibit 
lung carcinogenesis in mice. Nat Genet. 2001;29:25–33.  
39.  Qian Z, Zhu G, Tang L, Wang M, Zhang L, Fu J, et al. Whole genome gene copy number 
profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy 
targets. Genes Chromosom Cancer. 2014;53:883–94.  
40.  Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene 
amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 
2010;70:7580–90.  
41.  Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, et al. Identification of 
druggable cancer driver genes amplified across TCGA datasets. PLoS One. 2014;9.  
42.  Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, et al. K-RAS 
Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In 
Vivo. PLoS One. 2012;7.  
43.  Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of 
cell motility. Nat Rev Mol Cell Biol. 2005;6:56–68.  
44.  Kanteti R, Batra SK, Lennon FE SR. FAK and paxillin, two potential targets in pancreatic 
cancer. Oncotarget. 2016;7:31586–601.  
45.  McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG FM. The role of focal-
adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005;5:505–
15.  
46.  Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical 
applications. Nat Rev Cancer. 2014;14:598–610.  
47.  Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao X, et al. FAK Phosphorylation 
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
41 
by ERK Primes Ras-Induced Tyrosine Dephosphorylation of FAK Mediated by PIN1 and 
PTP-PEST. Mol Cell. 2009;35:11–25.  
48. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll N a, et al. A novel small
molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle.
2009;8:2435–43.
on May 7, 2018. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2017; DOI: 10.1158/0008-5472.CAN-17-2129 
 42 
FIGURE LEGENDS 
Figure 1: Sustained Kras knockdown in murine PDAC cells in vitro. 
A. Schematic of lentiviral constructs used to express the reverse tetracycline transactivator 
(rtTA) and doxycycline-inducible shRNA system.  PLTR = 5’-Long Terminal Repeat 
promoter from MSCV backbone.  PPGK = mouse phosphoglycerate kinase promoter.  Hygro = 
hygromycin resistance gene.  PTRE = tetracycline-response element minimal promoter.  GFP 
= green fluorescent protein.  Puro = puromycin resistance gene.  GFP mRNA and hairpins 
are on the same transcript. 
B. Kras mRNA levels following short-term (ST DOX, 4 days) or long-term (LT DOX, 21 days) 
DOX treatment of shLuc- or shKras-transduced cells.  Gene expression is normalized to 
untreated condition with TATA binding protein (TBP) control.  Average normalized Kras 
expression +/- 95% confidence intervals (n=3) of three independent clones from D parental 
cell line, using two independent hairpins and shLuc as control, is shown. 
C. Western blot showed sustained Kras protein knockdown following LT DOX treatment. 
D. Cell viability following ST (5 days) Kras knockdown normalized to untreated (No DOX) 
condition.  Average cell viability +/- s.d. (n=4) is shown.  *** p<0.001, two-tailed student t-
test. 
E. Phase-contrast images reveal morphological changes associated with ST and LT DOX 
treatment. 
F. Growth curves of untreated (No DOX) and LT DOX cells transduced with shKras or shLuc.  
Average cell viability (normalized to day 0) +/- s.d. (n=4) is plotted. 
 
Figure 2: The Kras-inhibited state is adaptive and reversible. 
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A. Clonal efficiency of Kras knockdown in four independent shKras clones (two from B line,
two from D line, of which one harbors shKras.923 and the other harbors shKras.1442) based
on the presence or absence of cells in wells plated with single cells. Clonal efficiency
appeared parental line- but not clone- or hairpin-dependent.  D line showed no difference in
clonal efficiency in the presence or absence of DOX.  B line showed a 25-35% decrease
under DOX treatment.  The majority of cells appeared to survive Kras knockdown.
****p<0.0001, chi-square test.
B. Quantitation of clone size 21 days after clonal expansion showed decreased clone size in LT
DOX cells.  Quantitation is based on solubilizaton of crystal violet stain and measurement of
absorbance at 540 nm shown as box plots with 5-95% confidence.  **** p<0.0001, two-
tailed student’s t-test with Welch correction for unequal variance.
C. Kras mRNA levels following DOX withdrawal (DOX WD) from LT DOX cells.  Gene
expression is normalized to untreated condition withTBP control.  Average normalized Kras
expression +/- 95% confidence intervals (n=3) of three independent clones from D line, using
two independent Kras hairpins and shLuc as control, is shown.
D. Reversal of cell morphology following DOX WD.  LT DOX images are same as Fig. 1F, as
DOX WD cells are derived from LT DOX cells.
E. Reversal of proliferative rates by colony forming assay following DOX WD.
F. Re-induced sensitivity to Kras knockdown with DOX treatment in reverted cells.  Cell
viability following ST (5 days) Kras re-knockdown normalized to untreated (No DOX)
condition.  Average cell viability +/- s.d. (n=4) is shown.  *** p<0.001, unpaired student t-
test comparing to No DOX condition.
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Figure 3: Characterization of tumor-initiating properties of Kras-inhibited PDAC cells. 
A. Quantitation showing parental cell line variation in the efficiency of tumorsphere formation 
in matrigel-based 3D cultures with Kras knockdown.  Average number of tumorspheres 
formed +/- s.d. (n=3) per 500 cells plated is shown. 
B. Tumorspheres imaged 12 days after plating demonstrated decreased size in LT DOX. 
C. Quantitation of tumor-initiating cell (TIC) number showed decreased TIC in LT DOX 
shKras-expressing cell lines. 
D. Secondary cell lines derived from LT DOX-treated shKras-expressing tumors retained GFP 
expression.  Phase-contrast and fluorescence images of representative secondary cell line at 
18 days post-tumor dissociation (2
nd
 LT DOX) are shown compared to the original cell line 
either untreated (No DOX) or treated with DOX for >21 days (LT DOX) in vitro. 
E. Kras mRNA levels of pre-transplant and secondary cell lines derived from LT DOX-
transplanted cells.  Gene expression is normalized to untreated (No DOX) condition with 
TBP control.  Average normalized Kras expression +/- 95% confidence intervals (n=3) is 
shown. 
F. Western blot of cell lines in (E) demonstrated decreased Kras protein levels in secondary cell 
lines comparable to original cell line treated with DOX in vitro prior to transplant. 
 
Figure 4: Gene expression analysis of Kras-inhibited cells shows minimal transcriptional 
changes. 
A. Unsupervised hierarchical clustering across all expressed genes from RNA-sequencing data 
demonstrated segregation based on parental cell line and clone rather than Kras knockdown 
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status (red box = no DOX, uninhibited; green box = LT DOX, Kras-inhibited). Multiple 
boxes of the same DOX condition for the same clone are replicates, which cluster together. 
B. Heatmaps of DOX and Kras knockdown (KD) signatures derived from independent 
component analysis of clone pairs in (A).  Columns represent distinct gene expression 
patterns (signatures), where colors encode directionality of gene expression and color 
intensity denotes strength of signature (Z-score) for each sample.   
C. DOX signature profile of individual cell line groups based on hairpin (shKras vs. shLuc) and 
DOX treatment conditions.  Higher scores indicate greater correlation of individual cell lines 
with DOX signature.  *p<0.05, Mann-Whitney U-test, comparing shKras/shLuc LT DOX vs. 
shKras/shLuc No DOX. 
D. Kras knockdown signature profile of individual cell line groups based on hairpin (shKras vs. 
shLuc) and DOX treatment.  Higher scores indicate greater correlation of individual cell lines 
with DOX signature.  *p<0.05, Mann-Whitney U-test, comparing shKras LT DOX vs. other 
groups. 
E. Network representation of overlapping enriched GSEA/MSigDB gene sets in the Kras 
knockdown signature (p<0.05, FDR<0.25).  Each circle represents a gene set with circle size 
corresponding to gene set size and intensity corresponding to enrichment significance.  Red 
is upregulated and blue is downregulated.  Each line corresponds to a minimum 50% mutual 
overlap with line thickness corresponding to the degree of overlap.  Cellular processes 
associated with related gene sets are listed. 
 
Figure 5: Unbiased phosphoproteomic analysis of signaling alterations in Kras-inhibited 
cells. 
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A. Western blot of total phospho-tyrosine levels (total pY) showed increased total pY in Kras-
inhibited cells.  Blue arrows indicate protein bands exhibiting increased intensity in Kras-
inhibited cells. 
B. Overlap of pY peptides between 3 technical replicates of iTRAQ experiments.  Criteria for 
such peptides are that they are unambiguously assigned, can be unique or not unique to a 
protein, phosphorylated, with an isolation interference ≤25 (low chance of contaminating or 
co-eluting peptides), and have a Mascot score of ≥25 (high confidence in the identification of 
the peptide). 
C. Scatter plot of the ratio (LT DOX/No DOX) of the abundance of pY sites identified in at 
least 2 iTRAQ experiments. Focal adhesion-associated proteins containing upregulated pY 
sites in the LT DOX state in both B (B shKras.923 cl1) and D (D shKras.1442 cl2) lines are 
labeled (green). Changes in peptide abundance significantly correlated between the two 
subclones analyzed (p<0.0001, R
2
 = 0.1875, Pearson correlation). 
D. Scatter plot of the log2 ratio (LT DOX/No DOX) of the abundance of pY sites identified in 
SILAC.  Focal adhesion-associated proteins containing upregulated pY sites in the LT DOX 
state in both B and D lines are labeled (green).  Changes in peptide abundance did not 





Figure 6: Kras-inhibited cells exhibit enhanced adherence properties and dependence. 
A. Immunofluorescence of vinculin revealed the distribution of focal adhesion plaques of No 
DOX and LT DOX cells.  Scale bar indicates 20μm.  
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B. Quantitation of the percentage of cells containing focal adhesion plaques.  Average % +/- s.d. 
(n=12) is shown.  **** p<0.0001, two-tailed student’s t-test, LT DOX vs. No DOX. 
C. Quantitation of focal adhesions per cell area (μm2).  Average +/- s.d. (n=8) is shown. * 
p<0.05, Mann-Whitney U-test, LT DOX vs. No DOX.  
D. Normalized cell number (LT DOX vs. No DOX) +/- s.d. (n=5) of adherent cells one hour 
after plating of single-cell suspension for shLuc and shKras-transduced clones derived from 
A and D lines.  *** p<0.001, **** p<0.0001, two-tailed student’s t-test, LT DOX vs. No 
DOX. 
E. Phase-contrast images of Kras-uninhibited (No DOX) and -inhibited (LT DOX) clone pairs 1 
hour after treatment with the actin polymerization inhibitor latrunculin B. 
F. Western blot showed increased expression of the apoptotic marker cleaved-caspase 3 (CC3) 
in Kras-inhibited cells after forced suspension growth for 48 hours. 
G. Normalized cell viability +/- s.e.m. (n=6) of cells grown in suspension with or without 2% 
matrigel.  Brightfield and fluorescence images of LT DOX tumorspheres maintaining GFP 
expression are shown. 
 
Figure 7: KRAS-inhibited 8988T cells exhibit altered cell proliferation and enhanced 
adherence properties and dependence. 
A. KRAS mRNA levels for no DOX, DOX-treated (10 days), and WD DOX (DOX for 5 days, 
no DOX for 5 days) of shLACZ.1650- or shKRAS.407-transduced 8988T cells.  Gene 
expression is normalized to untreated condition with beta-actin (ACTB) control.  Average 
normalized Kras expression +/- s.e.m. (n=2) is shown. 
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B. Cell viability following ST (5 days) KRAS knockdown normalized to untreated (No DOX) 
condition for 8988T cells transduced with inducible shLACZ.1650 (iLACZ) or shKRAS.407 
(iKRAS). WD: 8988T iKRAS-transduced cells treated with DOX for 5 days and then taken 
off DOX for 5 days restoring proliferation. WD cells exhibited reduced cell viability 
following repeat DOX treatment and KRAS knockdown.  Average cell viability +/- s.d. 
(n=5) is shown.  *** p<0.001, two-tailed student t-test comparing to No DOX condition). 
C. KRAS knockdown decreases colony forming ability of 8988T cells, which is partially 
reversed (proportional to the increase in KRAS expression in (A)) following DOX 
withdrawal (WD). 
D. Immunofluorescence of vinculin revealed the distribution of focal adhesion plaques of No 
DOX and LT DOX cells.  Scale bar indicates 20μm.  
E. Western blot showed increased expression of the apoptotic marker cleaved-PARP (cPARP) 
in KRAS-inhibited cells after forced suspension growth for 48 hours. 
F. Quantitation of the percentage of cells containing focal adhesion plaques.  Average % +/- s.d. 
(n=12) is shown.  **** p<0.0001, two-tailed student’s t-test for designated comparisons. 
G. Quantitation of the number of focal adhesions per cell area (μm2).  Average +/- s.d. (n=8) is 
shown. ** p<0.01, **** p<0.0001, two-tailed t-test for designated comparisons. 
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